EP0310542B1
(de)
*
|
1987-10-01 |
1994-06-08 |
Schering Aktiengesellschaft |
Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
|
DE3733478A1
(de)
*
|
1987-10-01 |
1989-04-13 |
Schering Ag |
Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
|
US4895715A
(en)
*
|
1988-04-14 |
1990-01-23 |
Schering Corporation |
Method of treating gynecomastia
|
GB8813353D0
(en)
*
|
1988-06-06 |
1988-07-13 |
Ici Plc |
Therapeutic product
|
HU208150B
(en)
*
|
1988-10-31 |
1993-08-30 |
Endorecherche Inc |
Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives
|
US5204337A
(en)
*
|
1988-10-31 |
1993-04-20 |
Endorecherche Inc. |
Estrogen nucleus derivatives for use in inhibition of sex steroid activity
|
US5686465A
(en)
*
|
1988-10-31 |
1997-11-11 |
Endorecherche Inc. |
Sex steroid activity inhibitors
|
US5393785A
(en)
*
|
1988-10-31 |
1995-02-28 |
Endorecherche, Inc. |
Therapeutic antiestrogens
|
US5395842A
(en)
*
|
1988-10-31 |
1995-03-07 |
Endorecherche Inc. |
Anti-estrogenic compounds and compositions
|
FR2643638B1
(fr)
*
|
1989-02-24 |
1991-06-14 |
Roussel Uclaf |
Nouveaux 19-nor steroides ayant en position 11beta une chaine carbonee comportant une fonction amide ou carbamate, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
|
US5364847A
(en)
*
|
1989-03-10 |
1994-11-15 |
Endorecherche |
Inhibitors of sex steroid biosynthesis and methods for their production and use
|
US5372996A
(en)
*
|
1989-03-10 |
1994-12-13 |
Endorecherche, Inc. |
Method of treatment of androgen-related diseases
|
IE62715B1
(en)
*
|
1989-03-10 |
1995-02-22 |
Endorecherche Inc |
Combination therapy for treatment of estrogen sensitive diseases
|
DE69034035T2
(de)
*
|
1989-07-07 |
2004-01-22 |
Endorecherche Inc., Ste-Foy |
Methode zur behandlung androgenbedingter krankheiten
|
AU5856090A
(en)
*
|
1989-07-07 |
1991-02-06 |
Endorecherche Inc. |
Androgen derivatives for use in the inhibition of sex steroid activity
|
DE3925507A1
(de)
*
|
1989-07-28 |
1991-01-31 |
Schering Ag |
14,17(alpha)-etheno- und ethanoestratriene, verfahren zur herstellung dieser verbindungen, sowie ihre verwendung zur herstellung von arzneimitteln
|
FR2654337B1
(fr)
*
|
1989-11-15 |
1994-08-05 |
Roussel Uclaf |
Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
|
ZA924811B
(en)
*
|
1991-06-28 |
1993-12-29 |
Endorecherche Inc |
Controlled release systems and low dose androgens
|
US6060503A
(en)
*
|
1991-12-02 |
2000-05-09 |
Endorecherche, Inc. |
Benzopyran-containing compounds and method for their use
|
KR950701527A
(ko)
*
|
1992-05-21 |
1995-04-28 |
라브리 페르낭 |
테스토스테론 5α 환원효소 활성 저해제(INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY)
|
DE19622457A1
(de)
|
1996-05-24 |
1997-11-27 |
Schering Ag |
7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
|
DE19635525A1
(de)
*
|
1996-08-20 |
1998-02-26 |
Schering Ag |
7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
|
US5866560A
(en)
|
1996-08-20 |
1999-02-02 |
Schering Ag |
7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
|
AU1110699A
(en)
*
|
1997-10-23 |
1999-05-10 |
American Home Products Corporation |
Estra-1,3,5(10)-triene-7alpha-thioethers
|
US6355630B1
(en)
|
1997-10-23 |
2002-03-12 |
American Home Products Corporation |
Estra-1,3,5(10)-triene-7α-thioethers
|
PE20000129A1
(es)
*
|
1997-12-23 |
2000-03-11 |
Schering Ag |
11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa
|
DE19807791A1
(de)
|
1998-02-19 |
1999-08-26 |
Schering Ag |
Kombinationspräparat aus Östrogen und Antiöstrogen
|
CA2330611A1
(en)
|
1998-05-22 |
1999-12-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Bifunctional molecules and therapies based thereon
|
GB0000313D0
(en)
|
2000-01-10 |
2000-03-01 |
Astrazeneca Uk Ltd |
Formulation
|
DE10027887A1
(de)
*
|
2000-05-31 |
2001-12-13 |
Jenapharm Gmbh |
Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
|
EP1304334A4
(en)
|
2000-06-30 |
2009-06-17 |
Chugai Pharmaceutical Co Ltd |
NEW ANTIANDROGEN AGENT
|
GB0025221D0
(en)
|
2000-10-14 |
2000-11-29 |
Astrazeneca Ab |
New process
|
US20050084908A1
(en)
*
|
2000-11-06 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for detecting binding of low-molecular-weight compound and its binding partner molecule
|
PL414997A1
(pl)
|
2001-02-19 |
2016-02-29 |
Novartis Ag |
Zastosowanie 40-O-(2-hydroksyetylo)-rapamycyny do leczenia guzów litych nerki
|
DE60219617T2
(de)
|
2001-05-16 |
2008-01-03 |
Novartis Ag |
Kombination von n- 5- 4-(4-methyl-piperazino-methyl)-benzoylamido -2-methylphenyl -4-(3-pyridil)-2pyrimidine-amin mit einem biphosphonat
|
GB0123961D0
(en)
*
|
2001-10-05 |
2001-11-28 |
Astrazeneca Ab |
Process and intermediates
|
DE10159217A1
(de)
*
|
2001-11-27 |
2003-06-05 |
Schering Ag |
17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
|
GB0128510D0
(en)
*
|
2001-11-28 |
2002-01-23 |
Novartis Ag |
Organic compounds
|
KR20120125398A
(ko)
|
2002-05-16 |
2012-11-14 |
노파르티스 아게 |
암에서 edg 수용체 결합제의 용도
|
NZ571508A
(en)
*
|
2002-05-24 |
2010-05-28 |
Schering Corp |
Neutralizing human anti-IGFR antibody
|
TW200526684A
(en)
*
|
2003-11-21 |
2005-08-16 |
Schering Corp |
Anti-IGFR1 antibody therapeutic combinations
|
JP4691549B2
(ja)
|
2004-04-07 |
2011-06-01 |
ノバルティス アーゲー |
Iapの阻害剤
|
CN100395259C
(zh)
*
|
2004-04-28 |
2008-06-18 |
江苏豪森药业股份有限公司 |
甾体类衍生物
|
US20050277625A1
(en)
*
|
2004-05-21 |
2005-12-15 |
Ralf Wyrwa |
Estriol and estetrol prodrugs
|
US7534780B2
(en)
*
|
2004-05-21 |
2009-05-19 |
Bayer Schering Pharma Aktiengesellschaft |
Estradiol prodrugs
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
US7790910B2
(en)
*
|
2004-07-27 |
2010-09-07 |
Sicor Inc. |
Process for the preparation of 7α-alkylated 19-norsteroids
|
JP5475235B2
(ja)
|
2005-01-21 |
2014-04-16 |
アステックス・セラピューティクス・リミテッド |
医薬化合物
|
MX2007012896A
(es)
*
|
2005-04-15 |
2007-12-10 |
Schering Corp |
Metodos y composiciones para tratamiento o prevencion de cancer.
|
SI1889198T1
(sl)
|
2005-04-28 |
2015-02-27 |
Proteus Digital Health, Inc. |
Farma-informacijski sistem
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
WO2007035716A2
(en)
|
2005-09-16 |
2007-03-29 |
Raptor Pharmaceutical Inc. |
Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
|
JP2009510073A
(ja)
|
2005-09-27 |
2009-03-12 |
ノバルティス アクチエンゲゼルシャフト |
カルボキシアミン化合物およびその使用方法
|
KR20070088695A
(ko)
*
|
2005-10-05 |
2007-08-29 |
시코르, 인크. |
풀베스트란트 이성질체의 분리 방법
|
ES2481671T3
(es)
|
2005-11-21 |
2014-07-31 |
Novartis Ag |
Inhibidores de mTOR en el tratamiento de tumores endocrinos
|
US20070123500A1
(en)
*
|
2005-11-29 |
2007-05-31 |
Gerd Mueller |
Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds
|
US20070197488A1
(en)
*
|
2005-11-29 |
2007-08-23 |
Olaf Peters |
Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
|
US20070135375A1
(en)
*
|
2005-11-30 |
2007-06-14 |
Ralf Wyrwa |
Sulfamoyl sulfonate prodrugs
|
US20070135399A1
(en)
*
|
2005-11-30 |
2007-06-14 |
Ralf Wyrwa |
Heteroaromatic sulphonamide prodrugs
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
EP2314297A1
(en)
|
2006-04-05 |
2011-04-27 |
Novartis AG |
Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
|
RU2447891C2
(ru)
|
2006-04-05 |
2012-04-20 |
Новартис Аг |
Комбинации терапевтических средств, предназначенные для лечения рака
|
CA2649792A1
(en)
|
2006-05-09 |
2007-11-15 |
Novartis Ag |
Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
|
ATE502943T1
(de)
|
2006-09-29 |
2011-04-15 |
Novartis Ag |
Pyrazolopyrimidine als pi3k-lipidkinasehemmer
|
EP2073803B1
(en)
|
2006-10-12 |
2018-09-19 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
US8883790B2
(en)
|
2006-10-12 |
2014-11-11 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
AU2008216327A1
(en)
|
2007-02-15 |
2008-08-21 |
Novartis Ag |
Combination of LBH589 with other therapeutic agents for treating cancer
|
US20100174101A1
(en)
*
|
2007-09-24 |
2010-07-08 |
Xi'an Liband Pharmaceutical Co., Ltd. |
Process for the manufacture of 7-alpha-[9-(4,4,5,5,5-penta fluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
|
US20090082323A1
(en)
*
|
2007-09-25 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched fulvestrant
|
CA2702710C
(en)
|
2007-10-16 |
2013-05-07 |
Repros Therapeutics, Inc. |
Trans-clomiphene for metabolic syndrome
|
EP2070941A1
(en)
|
2007-12-14 |
2009-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Stereoselective synthesis of selective estrogen receptor down-regulators
|
KR20100121505A
(ko)
*
|
2008-03-07 |
2010-11-17 |
싸이도우스 엘엘씨. |
플배스트랜 제제
|
ES2524259T3
(es)
|
2008-03-24 |
2014-12-04 |
Novartis Ag |
Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida
|
WO2009118305A1
(en)
|
2008-03-26 |
2009-10-01 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases b
|
US8063249B1
(en)
|
2008-04-25 |
2011-11-22 |
Olema Pharmaceuticals, Inc. |
Substituted triphenyl butenes
|
EP2350111A1
(en)
*
|
2008-10-15 |
2011-08-03 |
Synthon B.V. |
Processes and intermediates for the production of fulvestrant
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
US20110281917A1
(en)
|
2009-01-29 |
2011-11-17 |
Darrin Stuart |
Substituted Benzimidazoles for the Treatment of Astrocytomas
|
WO2010095940A2
(en)
|
2009-02-20 |
2010-08-26 |
To-Bbb Holding B.V. |
Glutathione-based drug delivery system
|
NZ596876A
(en)
|
2009-05-06 |
2014-01-31 |
Lab Skin Care Inc |
Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
|
EP2258375A1
(de)
|
2009-06-04 |
2010-12-08 |
Bayer Schering Pharma Aktiengesellschaft |
17B-alkyl-17alpha-oxy-estratriene
|
WO2010151133A1
(en)
|
2009-06-25 |
2010-12-29 |
Erasmus University Medical Center Rotterdam |
Methods for establishing and predicting resistance to endocrine therapy using an mirna profile
|
MY155570A
(en)
|
2009-06-26 |
2015-10-30 |
Novartis Ag |
1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
EA201200260A1
(ru)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
Гетероциклические гидразоны и их применение для лечения рака и воспаления
|
EA201200318A1
(ru)
|
2009-08-20 |
2012-09-28 |
Новартис Аг |
Гетероциклические оксимы
|
US20120149661A1
(en)
|
2009-08-26 |
2012-06-14 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
BR112012005400A2
(pt)
|
2009-09-10 |
2016-04-05 |
Irm Llc |
derivados do tipo éter de heteroarilas bicíclicas
|
CN102596951B
(zh)
|
2009-11-04 |
2015-04-15 |
诺华股份有限公司 |
用作mek抑制剂的杂环磺酰胺衍生物
|
JP2013512215A
(ja)
|
2009-11-25 |
2013-04-11 |
ノバルティス アーゲー |
二環式ヘテロアリールのベンゼン縮合6員酸素含有ヘテロ環誘導体
|
GEP20135998B
(en)
|
2009-12-08 |
2013-12-25 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
JP2013532149A
(ja)
|
2010-06-17 |
2013-08-15 |
ノバルティス アーゲー |
ピペリジニル置換1,3−ジヒドロ−ベンゾイミダゾール−2−イリデンアミン誘導体
|
CN102947274A
(zh)
|
2010-06-17 |
2013-02-27 |
诺瓦提斯公司 |
联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
|
DE102010030538A1
(de)
|
2010-06-25 |
2011-12-29 |
Bayer Schering Pharma Aktiengesellschaft |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
WO2012035078A1
(en)
|
2010-09-16 |
2012-03-22 |
Novartis Ag |
17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
|
EP2665493B1
(en)
|
2011-01-20 |
2018-03-21 |
Board Of Regents, The University Of Texas System |
Mri markers, delivery and extraction systems, and methods of manufacture and use thereof
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
JP2014507465A
(ja)
|
2011-03-08 |
2014-03-27 |
ノバルティス アーゲー |
フルオロフェニル二環式ヘテロアリール化合物
|
EP2702052B1
(en)
|
2011-04-28 |
2017-10-18 |
Novartis AG |
17alpha-hydroxylase/c17,20-lyase inhibitors
|
CA2838029A1
(en)
|
2011-06-09 |
2012-12-13 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
WO2012175487A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
WO2012175520A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
EA201490164A1
(ru)
|
2011-06-27 |
2014-04-30 |
Новартис Аг |
Твердые формы и соли производных тетрагидропиридопиримидина
|
MX339302B
(es)
|
2011-09-15 |
2016-05-19 |
Novartis Ag |
3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
|
US8969341B2
(en)
|
2011-11-29 |
2015-03-03 |
Novartis Ag |
Pyrazolopyrrolidine compounds
|
DE102011087987A1
(de)
|
2011-12-08 |
2013-06-13 |
Bayer Intellectual Property Gmbh |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
MD20140054A2
(ro)
|
2011-12-16 |
2014-10-31 |
Olema Pharmaceuticals, Inc. |
Compuşi noi de benzopiran, compoziţii şi utilizări ale acestora
|
EP2794594A1
(en)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Quinoline derivatives
|
LT2794600T
(lt)
|
2011-12-22 |
2018-02-26 |
Novartis Ag |
2,3-dihidro-benzo[1,4]oksazino dariniai ir giminingi junginiai kaip fosfoinozitido-3 kinazės (pi3k) inhibitoriai, skirti gydymui, pavyzdžiui, reumatoidinio artrito
|
AU2012355613A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
JP2015503516A
(ja)
|
2011-12-23 |
2015-02-02 |
ノバルティス アーゲー |
Bcl2と結合相手の相互作用を阻害するための化合物
|
EP2794591A1
(en)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
JP2015503517A
(ja)
|
2011-12-23 |
2015-02-02 |
ノバルティス アーゲー |
Bcl2と結合相手の相互作用を阻害するための化合物
|
EP2794592A1
(en)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
UY34591A
(es)
|
2012-01-26 |
2013-09-02 |
Novartis Ag |
Compuestos de imidazopirrolidinona
|
CN104093402A
(zh)
|
2012-01-31 |
2014-10-08 |
诺华股份有限公司 |
Rtk抑制剂与抗雌激素的组合及其治疗癌症的应用
|
ES2681023T3
(es)
|
2012-02-29 |
2018-09-11 |
Repros Therapeutics Inc. |
Terapia de combinación para tratar el déficit de andrógenos
|
US11179468B2
(en)
|
2012-04-09 |
2021-11-23 |
Eagle Pharmaceuticals, Inc. |
Fulvestrant formulations
|
US9365576B2
(en)
|
2012-05-24 |
2016-06-14 |
Novartis Ag |
Pyrrolopyrrolidinone compounds
|
SI3023415T1
(en)
|
2012-10-02 |
2018-01-31 |
Gilead Sciences, Inc. |
Histone demethylase inhibitors
|
JP2016027000A
(ja)
*
|
2012-10-09 |
2016-02-18 |
学校法人早稲田大学 |
ステロイド化合物及びこれを含有する医薬
|
US9315540B2
(en)
|
2012-10-22 |
2016-04-19 |
Intas Pharmaceuticals Ltd. |
Process for the preparation of fulvestrant
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
WO2014115077A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Substituted purinone compounds
|
US9556180B2
(en)
|
2013-01-22 |
2017-01-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
BR112015020650A2
(pt)
|
2013-02-27 |
2017-07-18 |
Epitherapeutics Aps |
inibidores de histona demetilases
|
EP2987799B1
(en)
*
|
2013-04-18 |
2020-04-08 |
Xi'an Libang Pharmaceutical Technology Co.,ltd. |
Ester derivative of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol having antitumour activity and preparation method thereof
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
WO2014203132A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Substituted benzopyran compounds, compositions and uses thereof
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
MY184292A
(en)
|
2013-09-22 |
2021-03-30 |
Sunshine Lake Pharma Co Ltd |
Substituted aminopyrimidine compounds and methods of use
|
MX2016009226A
(es)
|
2014-01-15 |
2016-10-05 |
Novartis Ag |
Combinaciones farmaceuticas.
|
CA2943979A1
(en)
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
EP3126345A1
(en)
|
2014-03-31 |
2017-02-08 |
Gilead Sciences, Inc. |
Inhibitors of histone demethylases
|
CN103980336B
(zh)
*
|
2014-05-21 |
2016-10-05 |
天津孚音生物科技发展有限公司 |
一种新的氟维司群的合成方法
|
CN103965280B
(zh)
*
|
2014-05-21 |
2016-04-20 |
天津孚音生物科技发展有限公司 |
一种氟维司群中间体的制备方法
|
WO2015181116A1
(en)
|
2014-05-26 |
2015-12-03 |
Crystal Pharma, S.A.U. |
Process and intermediades for the preparation of 7-alkylated steroids
|
EA201790154A1
(ru)
|
2014-08-27 |
2017-08-31 |
Джилид Сайэнс, Инк. |
Соединения и способы для ингибирования гистоновых деметилаз
|
EP3347097B1
(en)
|
2015-09-11 |
2021-02-24 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
|
KR20180071274A
(ko)
|
2015-10-01 |
2018-06-27 |
올레마 파마슈티컬스 인코포레이티드 |
테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
|
CN108348605B
(zh)
|
2015-11-10 |
2023-06-09 |
帕拉卡林治疗公司 |
用pdgf-cc抑制剂和抗雌激素治疗er阴性乳癌
|
MX2018007079A
(es)
|
2015-12-09 |
2018-11-12 |
The Board Of Trustees Of Univ Of Illinois |
Reguladores a la baja del receptor de estrogeno selectivo de benzotiofeno.
|
WO2018017410A1
(en)
|
2016-07-22 |
2018-01-25 |
Eli Lilly And Company |
Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
|
WO2018081168A2
(en)
|
2016-10-24 |
2018-05-03 |
The Board Of Trustees Of The University Of Illinois |
Benzothiophene-based selective mixed estrogen receptor downregulators
|
MX2019008158A
(es)
|
2017-01-06 |
2019-12-09 |
G1 Therapeutics Inc |
Terapia de combinacion para el tratamiento del cancer.
|
EP3710006A4
(en)
|
2017-11-19 |
2021-09-01 |
Sunshine Lake Pharma Co., Ltd. |
SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
|
EP3730483B1
(en)
|
2017-12-21 |
2023-08-30 |
Hefei Institutes of Physical Science, Chinese Academy of Sciences |
Class of pyrimidine derivative kinase inhibitors
|
US10751339B2
(en)
|
2018-01-20 |
2020-08-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
WO2021097256A1
(en)
|
2019-11-14 |
2021-05-20 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
CN115135649A
(zh)
|
2020-03-10 |
2022-09-30 |
正大天晴药业集团股份有限公司 |
包括吡啶并[1,2-a]嘧啶酮化合物的药物组合
|
IT202100003176A1
(it)
|
2021-02-12 |
2022-08-12 |
Farmabios Spa |
Processo per la preparazione di fulvestrant
|
CN114716496B
(zh)
*
|
2022-04-29 |
2024-04-02 |
香港中文大学(深圳) |
氟维司群衍生物及氟维司群衍生物制备方法和应用
|
CN116535454A
(zh)
*
|
2023-04-28 |
2023-08-04 |
香港中文大学(深圳) |
氟维司群类化合物及其制备方法和应用
|